Clinical trials: Pancreatic Adenocarcinoma Resectable
Borderline Resectable Pancreatic Cancer
IORT on Borderline Resectable Pancreatic Cancer
This phase II study investigates the efficacy of IORT for patients with borderline resectable pancreatic cancer. The purpose of the study is to investigate whether the addition of IORT, after FOLOFIRINOX-base chemotherapy, and…
- Trial name
- PancFORT (NCT04090463)
- Testing
- Intraoperative radiotherapy
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Universita di Verona
Pancreatic Ductal Adenocarcinoma
A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer
Pancreatic cancer is considered a rare form of cancer with about 277,000 new cases diagnosed in 2008 world-wide, which is about 2.5% of all forms of cancer.
- Trial name
- NCT01911416
- Testing
- LDE225
- Where
- United States
- Sponsor
- University of Utah
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a…
- Conditions
- Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Acinar Cell Carcinoma
- Trial name
- NCT04858334
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 456 sites in United States, Israel and 1 more
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)
Resectable Pancreatic Cancer, Pancreatic Ductal Carcinoma
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
This research study is a Phase II clinical trial, which evaluates a combination of drugs, FOLFIRINOX and Gemcitabine/Nab-Paclitaxel, in the management of participants with resectable pancreatic cancer prior to surgery.
- Trial name
- NCT02243007
- Testing
- FOLFIRINOX, Gemcitabine/nab-Paclitaxel, Radiation therapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8
Intravital Microscopy in Human Solid Tumors
This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated…
- Conditions
- Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma
- Trial name
- NCT03823144
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Mayo Clinic
Pancreatic Cancer
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
The survival rate for patients with pancreatic cancer remains at a dismal 10% or less at 5 years, and although trials integrating stereotactic body radiation therapy (SBRT) alone have shown improvement in local control, initial…
- Trial name
- NCT06141031
- Testing
- TTI-101, Stereotactic body radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Pancreatic Adenocarcinoma
Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma
To assess if percentage change in 18F-FLT PET/CT quantitative parameters (SUV max, or SUV peak or proliferative tumor volume) after 2 cycles of neoadjuvant chemotherapy can predict overall survival at 1 and 2 years and…
- Trial name
- NCT03318497
- Testing
- 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT, Computed Tomography, Positron Emission Tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Texas Southwestern Medical Center
Radical Antegrade Modular Pancreatosplenectomy
RAMPS VS SRPS for Pancreatic Body and Tail Adenocarcinoma
Two arms RCT is design, patients with pancreatic body or tail adenocarcinoma will be randomly assigned to the Radical Antegrade Modular Pancreaticosplenectomy (RAMPS) group or Standard Retrograde Pancreatosplenectomy (SRPS)…
- Trial name
- NCT04253847
- Testing
- Radical antegrade modular pancreatosplenectomy, Standard retrograde pancreatosplenectomy
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Ruijin Hospital
Skeletal Muscle Radiodensity, Myosteatosis
Prognostic Value of Myosteatosis and Creatinine-to-cystatin C Ratio in Patients With Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a 5-year survival rate as low as 6%. It causes body composition changes and many patients develop muscle loss with disease progression.
- Conditions
- Skeletal Muscle Radiodensity, Myosteatosis, Scr/CysC Ratio, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05584852
- Where
- China
- Volunteers
- 240 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Pancreatic Cancer Resectable, Pancreatectomy
Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)
The goal of this observational study is to determine how often lymph node metastases occur in the splenic hilum and surrounding fat in patients with left-sided pancreatic cancer.
- Trial name
- SPLENDID (NCT07157605)
- Where
- 10 sites in China, Greece and 6 more
- Volunteers
- 94 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer
This phase I trial studies the side effects of losartan and hypofractionated radiation therapy after chemotherapy in treating patients with pancreatic cancer that may or may not be removed by surgery (borderline resectable) or…
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
- Trial name
- SHAPER (NCT04106856)
- Testing
- Hypofractionated Radiation Therapy, Losartan, Losartan Potassium
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Utah
Pancreatic Neoplasms
Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region
This is a single center, single arm unblinded prospective study of the safety of pancreatic stereotactic body radiation therapy (SBRT) in patients with unresectable, borderline resectable, or recurrent pancreatic/periampullary…
- Trial name
- NCT02780648
- Testing
- Stereotactic Body Radiation
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Indiana University
Pancreatic Cancer
ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
To seek preliminary evidence of antitumor activity (progression free survival) of Erlotinib in combination with standard adjuvant chemoradiation and chemotherapy in patients with resected adenocarcinoma of the pancreas.
- Trial name
- NCT00313560
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Borderline Resectable Pancreatic Cancer
Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC
The aim of this study is to evaluate the safety and efficacy of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer
- Trial name
- NCT04855331
- Testing
- Laparoscopic pancreatoduodenectomy, Open pancreatoduodenectomy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer
This pilot clinical trial studies combination chemotherapy and radiation therapy before surgery followed by gemcitabine hydrochloride in treating patients with pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer
- Trial name
- NCT01821612
- Testing
- oxaliplatin, irinotecan, leucovorin
- Where
- 14 sites in United States
- Volunteers
- 23 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer.
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
- Trial name
- NCT04005690
- Testing
- Cobimetinib, Olaparib, Onvansertib
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- OHSU Knight Cancer Institute
Pancreatic Adenocarcinoma Resectable
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses of all human cancers and is considered as a sanctuary, resistant to most of the drugs used.
- Trial name
- NEOPACHI-001 (NCT01713218)
- Testing
- gemcitabine, Vismodegib, Neoadjuvant chemotherapy
- Where
- 2 sites in Belgium
- Volunteers
- 21 people
- Sponsor
- Jean-Luc Van Laethem
Pancreatic Adenocarcinoma Resectable
A Pilot Study of IRE for Resectable Pancreatic Cancer
The operation to remove certain pancreatic cancers (Whipple procedure), even in 2017, remains one of the most complicated surgeries done in the abdomen.
- Trial name
- NCT03337997
- Testing
- Irreversible Electroporation
- Where
- Canada
- Sponsor
- University of Saskatchewan
Pancreatic Ductal Adenocarcinoma
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic…
- Trial name
- NCT04969731
- Testing
- Immuncell-LC, Gemcitabine
- Where
- South Korea
- Volunteers
- 408 people
- Sponsor
- GC Cell Corporation
Adenocarcinoma of the Pancreas, Pancreas Cancer
Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B
Standard treatment for newly diagnosed operable pancreatic cancer usually involves undergoing surgery first and then receiving chemotherapy with or without radiation therapy.
- Trial name
- NCT03778879
- Testing
- CCX872-B
- Where
- United States
- Sponsor
- Alan Katz